RxDoctor Payments Data

Trevor Motter, PA

Physician Assistant · Henderson, NVNPI 1194350983

Payments from drug & device makers

$3,986in general payments, 2019–2025

Across 189 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$920
  • AstraZeneca$709
  • AbbVie$378
  • Boehringer Ingelheim$263
  • Pfizer$258
  • Novo Nordisk$212
  • plus $1K from 24 others

What the payments were for

  • Consulting fees$80020%
  • Food & beverage$3,18680%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,986 in reported general payments places this provider in the 85th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$30,336
Medicare patients
142
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$49,443
RybelsusSemaglutide15$31,178
EliquisApixaban14$20,750
JardianceEmpagliflozin12$18,612
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$13,257
Levothyroxine Sodium151$1,681
Atorvastatin Calcium166$1,266
Rosuvastatin Calcium101$1,249
Albuterol Sulfate HfaAlbuterol Sulfate44$907
Zolpidem Tartrate88$756
Gabapentin52$746
Losartan Potassium85$711
Omeprazole61$638
Ezetimibe27$600
Amlodipine Besylate103$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$212$80,62164 claims
PfizerEliquis$258$20,75014 claims
Boehringer IngelheimJardiance$263$18,61212 claims
AstraZenecaBreztri Aerosphere$709$13,25719 claims
Almatica Pharma LLCSertraline Hcl$34$31241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →